Acer Therapeutics Inc (ACER) is a leading biotechnology business based in the US. Acer Therapeutics is listed on the NASDAQ and employs 20 staff. All prices are listed in US Dollars.
|52-week range||$1.08 - $6.1|
|50-day moving average||$2.753|
|200-day moving average||$2.9662|
|Wall St. target price||$10|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.195|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Gross profit TTM||$0|
|Return on assets TTM||-66.68%|
|Return on equity TTM||-130.69%|
|Market capitalisation||$51.1 million|
TTM: trailing 12 months
There are currently 365,770 Acer Therapeutics shares held short by investors – that's known as Acer Therapeutics's "short interest". This figure is 12.1% down from 416,056 last month.
There are a few different ways that this level of interest in shorting Acer Therapeutics shares can be evaluated.
Acer Therapeutics's "short interest ratio" (SIR) is the quantity of Acer Therapeutics shares currently shorted divided by the average quantity of Acer Therapeutics shares traded daily (recently around 213900.58479532). Acer Therapeutics's SIR currently stands at 1.71. In other words for every 100,000 Acer Therapeutics shares traded daily on the market, roughly 1710 shares are currently held short.
However Acer Therapeutics's short interest can also be evaluated against the total number of Acer Therapeutics shares, or, against the total number of tradable Acer Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acer Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Acer Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0488% of the tradable shares (for every 100,000 tradable Acer Therapeutics shares, roughly 49 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Acer Therapeutics.
Find out more about how you can short Acer Therapeutics stock.
We're not expecting Acer Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Acer Therapeutics's shares were split on a 96:1000 basis on 21 September 2017. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 96 shares. This wouldn't directly have changed the overall worth of your Acer Therapeutics shares – just the quantity. However, indirectly, the new 941.7% higher share price could have impacted the market appetite for Acer Therapeutics shares which in turn could have impacted Acer Therapeutics's share price.
Over the last 12 months, Acer Therapeutics's shares have ranged in value from as little as $1.08 up to $6.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acer Therapeutics's is 1.3501. This would suggest that Acer Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of induced Vasomotor Symptoms. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.